Data from the Cancer Genome Atlas (TCGA) indicated that lung cancer patients (n = 573) with a high expression of LATS2 exerted higher overall survival rates than those (n = 572) with a low expression of LATS2 (Figure 3(d)), suggesting a tumor suppressive role for LATS2 in lung cancer [21]. Here, LATS2 is linked to lung carcinoma.